A phase I clinical study of inhaled nitric oxide in healthy adults

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 324-331

  Miller, Chris ^a   Miller, Minna ^a   McMullin, Bevin ^a,b   Regev, Gilly ^a   Serghides, Lena ^c   Kain, Kevin ^c   Road, Jeremy ^a   Av Gay, Yossef ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Respiratory Services   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Antimicrobial; Lung function; Methemoglobin; Nitric oxide; Phase I; Safety

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHEMOGLOBIN; NITRATE; NITRIC OXIDE; NITRITE; PROTHROMBIN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; EXPIRATORY RESERVE VOLUME; FEMALE; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; MALE; NORMAL HUMAN; ORAL PARESTHESIA; PROTEIN BLOOD LEVEL; SKIN BRUISING; TONGUE DISEASE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METHEMOGLOBIN; MIDDLE AGED; NITRIC OXIDE; NITRITES; OXYGEN; PULMONARY CIRCULATION; REFERENCE VALUES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84862489699     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.01.003     Document Type: Article

References (39)

1. Cystic Fibrosis 2007, Hodder Arnold, London. 3rd ed. M.E. Hodson, D. Geddes, A. Bush (Eds.).
2. Doring G., Hoiby N. Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
3. Döring G., Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 2009, 11:208-216.
4. Cystic Fibrosis Trust Antibiotic treatment for cystic fibrosis - report of the UK cystic fibrosis antibiotic working group 2009.
5. Tunney M.M., Field T.R., Moriarty T.F., Doering G., Muhlebach M.S., Wolfgang M.C., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177:995-1001.
6. Walsh C. Where will new antibiotics come from?. Nat Rev Microbiol 2003, 1:65-70.
7. Döring G., Meisner C., Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. PNAS 2007, 104:11020-11025. for the Flagella Vaccine Trial Study Group.
8. Liew F.Y., Cox F.E. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today 1991, 12:A17-A21.
9. Fang F.C. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004, 2:820-832.
10. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997, 15:323-350.
11. Meng Q.-H., Springall D.R., Bishop A.E., Morgan K., Evans T.J., Habib S., et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998, 184:323-331.
12. Grasemann H., Kurtz F., Ratjen F. Inhaled l-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 174:208-212.
13. Ratjen F., Gartig S., Wiesemann H.G., Grasemann H. Effect of inhaled nitric oxide on pulmonary function in cystic fibrosis. Respir Med 1999, 93:579-583.
14. Kelly T.J., Drumm M.L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998, 102:1200-1207.
15. McMullin B., Chittock D., Roscoe D., Garcha H., Wang L., Miller C. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated subjects in the ICU. Respir Care 2005, 50:1451-1456.
16. Ghaffari A., Neil D.H., Ardakani A., Road J., Ghahary A., Miller C.C. A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures. Nitric Oxide 2005, 12:129-140.
17. Ghaffari A., Jalili R., Ghaffari M., Miller C., Ghahary A. Efficacy of gaseous nitric oxide in the treatment of skin and soft tissue infections. Wound Repair Regen 2007, 15:368-377.
18. Miller C.C., Miller M.K., Ghaffari A., Kunimoto B. The treatment of chronic non-healing leg ulceration with gaseous nitric oxide - a case study. J Cutan Med Surg 2004, 8:233-238.
19. Miller C.C., McMullin B., Ghaffari A., Stenzler A., Pick N., Roscoe D., et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide 2009, 20:16-23.
20. Stenzler A, Miller C. Device and method for treatment of wounds with nitric oxide. US Patent 7520866.
21. Food and Drug Administration Approval of NDA 20-846 INOmax nitric oxide gas 1999.
22. Guidance for industry and for FDA reviewers - guidance document for premarket notification submissions for nitric oxide delivery apparatus, nitric oxide analyzer and nitrogen dioxide analyzer Jan. 24 2000.
23. Borgese N., Pietrini G., Gaetani S. Concentration of NADH-cytochrome b5 reductase in erythrocytes of normal and methemoglobinemic subjects measured with quantitative radioimmunoblotting assay. J Clin Invest 1987, 80:1296-1302.
24. Young J.D., Dyar O., Xiong L., Hoell S. Methaemoglobin production in normal adults inhaling low concentrations of nitric oxide. Intensive Care Med 1994, 20:581-584.
25. Young J.D., Sear J.W., Valvini E.M. Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. Br J Anaesth 1996, 76:652-656.
26. Hurford W. Nitric oxide as a bactericidal agent: is the cure worse than the disease?. Respir Care 2005, 50:1428-1429.
27. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982, 126:131-138.
28. INOmax (nitric oxide) for inhalation Prescribing information http://inomax.com/assets/pdf/INOmax-PI-web-0909.pdf.
29. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17205-17208.
30. Miller C.C., Rawat M., Johnson T., Av-Gay Y. Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother 2007, 51:3364-3366.
31. Dupuy P.M., Shore S.A., Drazen J.M., Frostell C., Hill W.A., Zapol W.M. Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest 1992, 90:421-428.
32. O'Shea J.J. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity 1997, 7:1-11.
33. Conroy A.L., Phiri H., Hawkes M., Glover S., Mallewa M., Seydel K.B., et al. Endothelium-based biomarkers are associated with cerebral malaria in Malwian children: a retrospective case-control study. PLoS One 2010, 5:e15291.
34. Ricciuto D.R., Dos Santos C.C., Hawkes M., Toltl L.J., Conroy A.L., Rajwans N., et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011, 39:702-710.
35. Webert K.E., Vanderzwan J., Duggan M., Scott J.A., McCormack D.G., Lewis J.F., et al. Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit Care Med 2000, 28:2397-2405.
36. Jean D., Maitre B., Tankovic J., Meignan M., Adnot S., Brun-Buisson C., et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 2002, 30:442-447.
37. Long R., Talbot J., Mayers R.L., Jones R.L. Treatment of sputum-smear positive pulmonary tuberculosis with inhaled nitric oxide. Antimicrob Agents Chemother 2005, 49:1209-1212.
38. Hergott C.A., Rohan M., Farley K., McCormack D.G., Mehta S. Effects of continuous vs pulsed inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2006, 173:A135.
39. Schaefer A.L., Perry B.J., Cook N.J., Miller C., Church J., Tong A.K.W., et al. Infrared detection and nitric oxide treatment of bovine respiratory disease (BRD). Online J Vet Res 2006, 10:7-16.